Clinical Research Directory
Browse clinical research sites, groups, and studies.
Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Summary
The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life. The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments. Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation. The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.
Official title: Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
347
Start Date
2025-05-12
Completion Date
2031-10
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
Radiotherapy (CTV=10mm)
Radiotherapy with reduced irradiation volume CTV=10mm
Radiotherapy (CTV=15mm)
Radiotherapy with standard irradiation volume CTV=15mm
Locations (23)
Olv Azorg
Aalst, Belgium
EpiCURA
Baudour, Belgium
AZ Sint Jan
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
UZ Brussel
Brussels, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
Ziekenhuis Oost-Limburg (ZOL)
Genk, Belgium
AZ Sint-Lucas
Ghent, Belgium
UZ Gent
Ghent, Belgium
Grand Hôpital de Charleroi
Gilly, Belgium
JESSA Ziekenhuis
Hasselt, Belgium
AZ Groeninge
Kortrijk, Belgium
Chu Helora
La Louvière, Belgium
UZ Leuven
Leuven, Belgium
CHU Liège
Liège, Belgium
AZ Sint Maarten
Mechelen, Belgium
Hôpital André Vésale - HUmani
Montigny-le-Tilleul, Belgium
CH Mouscron
Mouscron, Belgium
CHU UCL Namur - Sainte Elisabeth
Namur, Belgium
AZ Delta
Roeselare, Belgium
Cliniques de l'Europe
Uccle, Belgium
CHR Verviers
Verviers, Belgium
ZAS Augustinus
Wilrijk, Belgium